X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (59) 59
humans (42) 42
animals (39) 39
antidepressive agents, second-generation - pharmacology (35) 35
male (33) 33
neurosciences (33) 33
rats (28) 28
chronic myeloid leukemia (26) 26
psychiatry (25) 25
female (24) 24
oncology (24) 24
pharmacology & pharmacy (22) 22
antidepressants (20) 20
fluoxetine - pharmacology (20) 20
fluoxetine (18) 18
tyrosine (16) 16
hematology (15) 15
depression (14) 14
imatinib (14) 14
adult (13) 13
brain (12) 12
rats, sprague-dawley (12) 12
second-generation tyrosine kinase inhibitors (12) 12
analysis (11) 11
chronic myelogenous leukemia (11) 11
dose-response relationship, drug (11) 11
drug therapy (11) 11
middle aged (11) 11
protein kinase inhibitors - therapeutic use (11) 11
antineoplastic agents - therapeutic use (10) 10
clinical neurology (10) 10
hippocampus - drug effects (10) 10
nilotinib (10) 10
treatment outcome (10) 10
aged (9) 9
cancer (9) 9
dasatinib (9) 9
disease models, animal (9) 9
hippocampus (9) 9
hippocampus - metabolism (9) 9
messenger-rna (9) 9
mice (9) 9
research (9) 9
resistance (9) 9
second generation (9) 9
serotonin (9) 9
biomedicine (8) 8
chemotherapy (8) 8
clinical trials (8) 8
gene-expression (8) 8
imatinib mesylate (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (8) 8
physiological aspects (8) 8
protein-tyrosine kinase (8) 8
tyrosine kinase inhibitor (8) 8
antidepressive agents, second-generation - adverse effects (7) 7
antidepressive agents, second-generation - therapeutic use (7) 7
antidepressive agents, tricyclic - pharmacology (7) 7
chronic-phase (7) 7
cml (7) 7
depression - drug therapy (7) 7
kinases (7) 7
medicine & public health (7) 7
mutation (7) 7
neurotrophic factor (7) 7
open-label (7) 7
patients (7) 7
serotonin uptake inhibitors - pharmacology (7) 7
signal transduction - drug effects (7) 7
survival (7) 7
1st-line treatment (6) 6
antidepressant (6) 6
behavior, animal - drug effects (6) 6
biochemistry & molecular biology (6) 6
cells (6) 6
depression, mental (6) 6
dosage and administration (6) 6
epidermal growth factor (6) 6
growth-factor receptor (6) 6
health aspects (6) 6
lung cancer (6) 6
major depression (6) 6
original (6) 6
paroxetine (6) 6
paroxetine - pharmacology (6) 6
phenols (6) 6
proteins (6) 6
proteomics (6) 6
pyrimidines - therapeutic use (6) 6
rat hippocampus (6) 6
second-generation tyrosine kinase inhibitor (6) 6
afatinib (5) 5
aged, 80 and over (5) 5
antidepressant drugs (5) 5
antidepressive agents - pharmacology (5) 5
benzamides (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
cell line, tumor (5) 5
cells, cultured (5) 5
chronic myeloid-leukemia (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Hematology, ISSN 0925-5710, 6/2018, Volume 107, Issue 6, pp. 712 - 715
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2014, Volume 14, Issue 2, pp. 155 - 162.e1
Journal Article
Annals of Hematology, ISSN 0939-5555, 11/2015, Volume 94, Issue 11, pp. 1891 - 1897
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 10/2015, Volume 9, pp. 5641 - 5653
EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring... 
Dacomitinib | EGFR T790M | Epidermal growth factor receptor (EGFR) | Tyrosine-kinase inhibitor (TKI) | Second-generation EGFR TKI | Tyrosine | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Kinases | Cancer therapies | Patients | Studies | Chemotherapy | Randomization | Epidermal growth factor | Platinum | Mutation | Gefitinib | Drug dosages
Journal Article
by Ou, SHI and Soo, RA
DRUG DESIGN DEVELOPMENT AND THERAPY, ISSN 1177-8881, 2015, Volume 9, Issue default, pp. 5641 - 5653
EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring... 
1ST-LINE TREATMENT | GEFITINIB | CHEMISTRY, MEDICINAL | second-generation EGFR TKI | epidermal growth factor receptor (EGFR) | dacomitinib | PHASE-III | ACQUIRED-RESISTANCE | KOREAN PATIENTS | OPEN-LABEL | EGFR T790M | tyrosine-kinase inhibitor (TKI) | GROWTH-FACTOR RECEPTOR | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | ERLOTINIB | PRIOR CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Patient Selection | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Drug Design | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Quinazolinones - therapeutic use | Quinazolinones - adverse effects | Antimitotic agents | Antineoplastic agents | Drug therapy | Lung cancer | Testing
Journal Article
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 05/2017, Volume 20, Issue 5, p. A92
OBJECTIVES: To compare the effectiveness, as measured by complete molecular response (CMR) and 2- and 3-year overall survival (OS), of ponatinib versus first-... 
Tyrosine | Corticoids | Second generation | Autografts | Imatinib | Inhibitor drugs | Acute lymphatic leukemia | Corticosteroids | Leukemia | Newly diagnosed | Clinical trials | Efficacy | Lymphatic leukemia | Combination therapy | Patients | Meta-analysis | Literature reviews | Confidence intervals | Chemotherapy | Protein-tyrosine kinase
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 2018, Volume 41, Issue 3, pp. 213 - 217
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 2015, Volume 11, Issue 18, pp. 2525 - 2540
First-generation reversible EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) changed our understanding of advanced non-small-cell lung cancer biology and... 
1ST-LINE TREATMENT | ErbB2 | second generation | ErbB4 | irreversible | ACQUIRED-RESISTANCE | adenocarcinoma | INTERMITTENT ERLOTINIB | FAMILY BLOCKER | afatinib | GROWTH-FACTOR RECEPTOR | squamous | PHASE-II TRIAL | ONCOLOGY | BRAIN METASTASES | EGF receptor | OPEN-LABEL TRIAL | tyrosine kinase inhibitor | QUALITY-OF-LIFE | ADVERSE EVENTS | non-small-cell lung cancer
Journal Article
Leukemia Research, ISSN 0145-2126, 2009, Volume 34, Issue 2, pp. 143 - 147
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2013, Volume 160, Issue 5, pp. 630 - 639
The BCR-ABL1 transcript level at 3months can predict long-term outcomes following frontline therapy with Imatinib or Dasatinib in chronic myeloid leukaemia... 
BCR-ABL1 transcript level | Chronic myeloid leukaemia | Second generation tyrosine kinase inhibitor | MESYLATE | INTERFERON | CYTOGENETIC RESPONSE | second generation tyrosine kinase inhibitor | CYTARABINE | HEMATOLOGY | FAILURE | chronic myeloid leukaemia
Journal Article
Clinical and Translational Oncology, ISSN 1699-048X, 4/2014, Volume 16, Issue 4, pp. 339 - 350
Journal Article
Journal Article